Full-Time

Senior Project Manager

NPI

Updated on 8/1/2026

Stryker

Stryker

10,001+ employees

Manufactures orthopedic and surgical medical devices

No salary listed

Carrigtohill, Carrigtwohill, Co. Cork, Ireland

Hybrid

Hybrid or on-site in Anngrove, Cork; approximately 10% travel required.

Category
Business & Strategy (1)
Required Skills
Supply Chain Management
Six Sigma
Risk Management

Get referred to Stryker

See people who can refer or advise you

Requirements
  • A bachelor's degree in an engineering or science discipline or equivalent is required.
  • Experience in project management within an engineering or regulated industry is essential, with demonstrated ability to plan, prioritize, multitask, and organize multidisciplinary teams to achieve project deliverables.
  • Applied knowledge of United States Food and Drug Administration and international medical device regulations.
  • Ability to lead, motivate, and influence cross-functional teams on moderately complex projects, including teams that do not report directly to the position.
  • Excellent analytical and problem-solving skills, including risk management experience.
Responsibilities
  • Lead implementation of manufacturing processes and associated supply chain systems supporting the development and commercial launch of new product programs.
  • Define project scope, plan and execute projects, and ensure delivery on time, within budget, and in alignment with performance requirements.
  • Deliver the manufacturing element of new product programs, focusing on scope setting, project planning and management, product quality, budget management, product supply management, and Design for Manufacture.
  • Lead project teams comprising professionals from Quality, Sterilization, Production, Packaging, Labelling, Materials, Logistics, Finance, Industrial Engineering, Human Resources, Process Engineering, Facilities, and Environment, Health and Safety, and assume responsibility for assigned teams and operational deliverables.
  • Collaborate with manufacturing-site leadership during design development to introduce new manufacturing processes into production compliantly, on time, within budget, operationally successfully, and in alignment with the broader plant manufacturing strategy.
  • Ensure quality management system deliverables are completed to transfer products from design development into commercialization.
  • Drive the capital acquisition strategy by determining total capital expenditure and operational expense, obtaining internal approvals, supporting contract negotiations, and ensuring timely installation, qualification, and validation.
  • Develop a comprehensive communication plan and strategy to convey project status updates to stakeholders in Commercial and Operational business forums.
  • Liaise with Regulatory Affairs to align project strategy with the required regulatory pathway and applicable regulations.
  • Integrate additive manufacturing technologies to support the launch of a new custom implant and enable future divisional applications.
Desired Qualifications
  • Project management certification through an accredited organization.
  • Experience in process validation.
  • Experience delivering results through Six Sigma and lean methods.

Stryker designs, manufactures, and sells medical devices across multiple areas, including surgical equipment, neurotechnology, and orthopedic implants, to hospitals and clinics worldwide. Its products are developed through engineering and clinical input, then manufactured and distributed to healthcare providers who use them during procedures to improve patient care and surgical efficiency. Stryker differentiates itself from competitors with a broad, integrated portfolio, a global sales and service network, and a strong emphasis on quality and ongoing product development to support safer, more efficient procedures. The company’s goal is to advance patient outcomes by delivering reliable, effective medical devices that expand access to care globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kalamazoo, Michigan

Founded

1941

Get referred to Stryker

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Stryker reported $25.1 billion global sales in 2025.
  • Strong free cash flow supports R&D, launches, and acquisitions.
  • Valuation around 22x forward earnings leaves room for multiple expansion.

What critics are saying

  • March 2026 cyberattack disrupted operations and raises repeat outage risk.
  • Softer healthcare utilization threatens procedure volumes and margin expansion.
  • Pangea adoption delays could leave trauma share exposed to incumbents.

What makes Stryker unique

  • Mako robotics anchors Stryker's orthopedic franchise and surgeon workflow integration.
  • Pangea Plating System broadens trauma coverage across variable-angle fracture fixation.
  • Inari acquisition accelerated Vascular growth, showing repeatable tuck-in integration.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Medical & prescription plans

Supplemental health benefits

Flexible Spending accounts

Employee Assistance Program

Short-term & long-term disability

Tuition reimbursement

401(k) plan

Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
ASC News
Apr 13th, 2026
ASC Technology Roundup: Distalmotion Files for Expanded Robotic Gynecology Clearance; Stryker, Medtronic Make Acquisitions

Distalmotion targets ASC gynecology programs with new FDA filing Distalmotion has submitted a 510(k) application to the FDA seeking to expand the label of its Dexter robotic surgery system into additional gynecological indications, the company announced April 1. The filing covers sacrocolpopexy, sacrocervicopexy and endometriosis resection. Sacrocolpopexy and sacrocervicopexy are procedures used to treat pelvic…

Market Wire News
Apr 13th, 2026
Stryker to acquire Amplitude Vascular Systems, adding next-gen IVL tech to peripheral vascular portfolio

Stryker Corporation has signed a definitive agreement to acquire Amplitude Vascular Systems, a Boston-based medical technology company developing next-generation intravascular lithotripsy technology for treating calcified peripheral arterial disease. Financial terms were not disclosed. AVS's technology uses pulsed CO₂-generated pressure waves delivered through a balloon catheter to fracture calcium deposits. The platform aims to enhance catheter deliverability, treatment speed and therapy efficiency. The acquisition will strengthen Stryker's peripheral vascular portfolio and expand its presence in arterial disease treatment. Stryker CEO Kevin Lobo said the deal advances the company's vision to build a comprehensive peripheral vascular platform addressing significant clinical needs. IVL technology is experiencing strong growth as physicians increasingly adopt it for calcium modification in complex cardiovascular procedures. The transaction remains subject to customary closing conditions.

Yahoo Finance
Mar 18th, 2026
Stryker posts 11% Q4 growth amid tariff pressures, margin expansion continues

Stryker has raised $120 million in a Series C round led by Ribbit Capital, valuing the medical technology company at $1.45 billion. The funding comes despite shares declining 7.6% over the past six months, outperforming the industry's 19.7% drop. The company delivered 11% organic sales growth in Q4 2025 and 10.3% for the full year, marking its fourth consecutive year of double-digit growth. Performance was broad-based across its Orthopaedics, MedSurg and Neurotechnology segments, driven by strong procedural volumes and favourable demographics. Stryker achieved over 100 basis points of operating margin expansion for the second consecutive year despite tariff pressures. The company enters 2026 with a robust capital equipment backlog, though rising interest costs and tariffs present near-term challenges. Analysts maintain a Hold rating on the stock.

Yahoo Finance
Mar 13th, 2026
Stryker shares fall 9% to $339 after Iranian cyberattack wipes 200,000+ systems

Stryker shares fell 9% to $339 following a destructive cyberattack by Iranian-linked group Handala that wiped over 200,000 systems and disrupted manufacturing and shipping operations across 56,000 employees in 61 countries. The medical technology company confirmed disruptions to order processing but stated there was no indication of ransomware. Unlike typical ransomware attacks, this wiper attack permanently deleted data rather than holding it for ransom, complicating recovery efforts. The incident threatens Stryker's 8% to 9.5% organic growth guidance for 2026 if operations fail to normalise quickly. Stryker generated $25 billion in revenue in 2025 with $4.283 billion in free cash flow and holds $4 billion in cash. Analysts maintain a consensus price target of $424.89 with 22 buy ratings and no sell ratings among 30 covering analysts.

Yahoo Finance
Mar 12th, 2026
Stryker reports 11.4% revenue growth in Q4, beating estimates with $7.17B

Stryker reported Q4 revenues of $7.17 billion, up 11.4% year-over-year and exceeding analyst expectations by 0.8%. The medical device manufacturer, which impacts over 150 million patients annually through its orthopaedics, surgical tools, neurotechnology and patient care solutions, delivered what CEO Kevin Lobo called "an outstanding finish to 2025". The company achieved double-digit sales and adjusted earnings per share growth for both the quarter and full year, whilst expanding adjusted operating margin by at least 100 basis points for the second consecutive year. Across the medical devices and supplies sector, the six diversified stocks tracked reported mixed Q4 results. As a group, revenues beat consensus estimates by 1.9%, though share prices have declined an average of 5.1% since the latest earnings announcements.